Loading...

Fujifilm has recovered from its slump and is now a phoenix

Published
07 May 26
Views
48
07 May
JP¥3,401.00
kapirey's Fair Value
JP¥2,746.00
23.9% overvalued intrinsic discount
Loading
1Y
9.3%
7D
-3.6%

Author's Valuation

JP¥2.75k23.9% overvalued intrinsic discount

kapirey's Fair Value

I recommend that you read the Fujifilm Group Business Overview; this document defines the company's objectives up to 2030.

Based on that report and the latest published results, I used Copilot to synthesize the most relevant information and create this report.

Political risks are high, and the support of its main shareholders and international partners in Japan is uncertain, so I've raised the risk to 9%.

I believe Fujifilm has recovered from its slump and is now a phoenix. This is why I'm maintaining my investment despite the losses it has generated.

🧭 FUJIFILM – McKinsey 3 Horizons Strategy

📌 Overview

The McKinsey 3 Horizons model categorizes businesses into:

  • Horizon 1 (H1): Core / cash-generating businesses
  • Horizon 2 (H2): Emerging growth businesses
  • Horizon 3 (H3): Future opportunities / innovation bets

FUJIFILM is a multi-horizon company in transition, balancing legacy revenues with fast-growing technology and healthcare bets.

🟢 Horizon 1 – Core Business (Defend & Optimize)

🔹 Main Activities

  • Business Innovation (office solutions, printing)
  • Parts of Healthcare (medical equipment)
  • Mature Imaging segments

🔹 Evidence (2025)

  • Business Innovation:
    • Revenue: ¥850Bn (largest segment, 35%)
    • Growth: −1.4% (declining)
  • Healthcare margins relatively low (~4.4%)

🔹 Strategic Role

  • Stable revenue base
  • Cash generation (though declining)
  • Customer relationships and installed base

⚠ Challenges

  • Structural decline (printing, office hardware)
  • Weak profitability vs newer segments
  • Regional weakness (Asia-Pacific)

🎯 Strategic Actions

  • Cost optimization and automation
  • Shift to digital services (DX solutions)
  • Exit low-margin products
  • Focus on recurring services

👉 Goal: Extend lifecycle and maximize cash flow

🟡 Horizon 2 – Growth Engines (Scale & Expand)

🔹 Main Activities

  • Imaging (instax, digital cameras)
  • Electronics (semiconductor materials)
  • Parts of Healthcare (biotech CDMO)

🔹 Evidence (2025)

  • Imaging:
    • Revenue: ¥485.7Bn (+13.8%)
    • Margin: 27.9%
  • Electronics:
    • Revenue: ¥328.7Bn (+6.9%)
    • Profit: +22.2%

🔹 Strategic Role

  • High growth and high profitability
  • Key contributors to margin expansion
  • Bridge between legacy and future

🚀 Growth Drivers

  • AI-driven semiconductor demand
  • Strong global brand (instax)
  • Expansion in high-end imaging and cameras

⚠ Challenges

  • Competitive pressure in semiconductors
  • Cyclical demand
  • Need for continuous innovation

🎯 Strategic Actions

  • Increase capacity and global production
  • Invest in R&D and product differentiation
  • Strengthen global distribution

👉 Goal: Scale into dominant high-margin businesses

🔵 Horizon 3 – Future Bets (Invest & Build)

🔹 Main Activities

  • Bio CDMO (biopharma manufacturing)
  • AI-driven healthcare solutions
  • Advanced materials for next-gen tech

🔹 Evidence (2025)

  • Strong investment in:
    • New biotech plants (US, Denmark)
  • High CAPEX → negative free cash flow (−¥164.5Bn)

🔹 Strategic Role

  • Long-term transformational growth
  • Entry into high-value, high-barrier industries
  • Future profit and valuation driver

🚀 Opportunities

  • Growing global demand for biologics manufacturing
  • AI-driven diagnostics and surgery systems
  • Integration with digital health ecosystems

⚠ Risks

  • Long payback periods
  • Execution complexity
  • Regulatory exposure

🎯 Strategic Actions

  • Continue strategic investments
  • Build partnerships in pharma & AI
  • Scale production capabilities globally

👉 Goal: Create next-generation core businesses

⚖️ Portfolio Balance Analysis

Horizon

Business Areas

Role

Risk

Return

H1

Business Innovation, legacy healthcare

Stability

Low growth

Medium

H2

Imaging, Electronics

Growth

Moderate

High

H3

Biotech, AI healthcare

Transformation

High

Very High

🧠 Strategic Insights

1. Strong shift toward H2 and H3

FUJIFILM is actively reallocating resources:

  • From declining office/printing
  • Toward semiconductors, biotech, AI

👉 Evidence: CAPEX increase and segment growth differences

2. Profitability is already moving to H2

  • Imaging and Electronics drive margins
  • Legacy segments drag overall performance

👉 Indicates a successful early transformation phase

3. H3 investments are critical but risky

  • Negative free cash flow due to expansion 👉 Company is trading short-term cash for long-term positioning

4. Key strategic tension

FUJIFILM must balance:

  • Funding H3 investments
  • While maintaining H1 cash flow
  • And accelerating H2 growth

🎯 Final Strategic Recommendation

✅ PRIORITY 1: Accelerate H2 dominance

  • Scale semiconductor and imaging leadership
  • Focus on margin expansion

✅ PRIORITY 2: Monetize H3 investments

  • Speed up commercialization in biotech
  • Build global partnerships

✅ PRIORITY 3: Manage H1 decline

  • Optimize cost structure
  • Transform into service-based model

🏁 Conclusion

FUJIFILM is a textbook example of a company moving across the 3 horizons:

  • Past: Imaging & printing company
  • Present: Diversified tech leader
  • Future: Healthcare + AI + semiconductor ecosystem player

👉 Its success will depend on how effectively it:

  • Scales Horizon 2
  • Executes Horizon 3
  • And manages the decline of Horizon 1

Have other thoughts on FUJIFILM Holdings?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

The user kapirey has a position in TSE:4901. Simply Wall St has no position in any of the companies mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The author of this narrative is not affiliated with, nor authorised by Simply Wall St as a sub-authorised representative. This narrative is general in nature and explores scenarios and estimates created by the author. The narrative does not reflect the opinions of Simply Wall St, and the views expressed are the opinion of the author alone, acting on their own behalf. These scenarios are not indicative of the company's future performance and are exploratory in the ideas they cover. The fair value estimates are estimations only, and does not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that the author's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Read more narratives